ANEMIA DRUG PULLED FROM MARKET AFTER FATAL ALLERGIC REACTIONS
Omontys (peginesatide) is a pharmaceutical drug prescribed to patients suffering from anemia due to chronic kidney disease on dialysis. Omontys is administered either intravenously or subcutaneously. The dangerous drug was marketed and distributed by Takeda Pharmaceuticals. Omontys is a man-made form of a protein that helps the body produce red blood cells.
Common side effects of Omontys include:
- Difficulty breathing
- Shortness of breath
- Pale skin
- Joint pain
- Cold symptoms
The drug received approval by the U.S. Food and Drug Administration in 2012, but would be on the market for less than a full year.
OMONTYS LINKED TO LIFE-THREATENING ANAPHYLAXIS
Peginesatide drug label contains a black box warning regarding the increased risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression and recurrence. Omontys is an erythropoiesis-stimulating agent (ESA), which has been linked to these severe risks.
However, the drug maker issued a recall on all lots of the dangerous medication due to incidents relating to serious hypersensitivity reactions. There have been numerous reports of patients sustaining serious allergic reactions to the drug, including anaphylaxis, and unfortunately some of these incidents lead to deaths. In February 2013, the drug maker pulled Omontys off the shelves.
HARMED BY A RECALLED DRUG? CONTACT OUR EXPERIENCED DRUG LAWYERS
If you or a loved one were injured after taking a dangerous, recalled drug like Omontys, contact Thomas J. Henry. Our firm has the legal and financial resources you need to take on the pharmaceutical giants and develop your case properly. Our experienced team of pharmaceutical drug litigation attorneys are available 24/7, nights and weekends to evaluate your case and provide you with a free legal consultation. Contact us today.